-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TD3tP9CbZ/4CMFZ/V3wlJbneni6b7lxbxA0bmLC94ZE75VHKCUcia0qWg09IielK unLogX0cSvywyHHBkF7urw== 0000950133-06-000681.txt : 20060214 0000950133-06-000681.hdr.sgml : 20060214 20060214103728 ACCESSION NUMBER: 0000950133-06-000681 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20051231 FILED AS OF DATE: 20060214 DATE AS OF CHANGE: 20060214 EFFECTIVENESS DATE: 20060214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-06964 FILM NUMBER: 06607989 BUSINESS ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 13F-HR 1 w17511ae13fvhr.txt FORM 13F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 13F Form 13F COVER PAGE Report for Calendar Year or Quarter Ended: December 31, 2005 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: BB Biotech AG Address: Vordergasse 3 Schaffhausen Switzerland CH-8200 Form 13F File Number: 28-6964 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Adrian Bruengger Title: SIGNING AUTHORITY Phone: 41 (01) 267 67 00 Signature, Place, and Date of Signing: /s/ ADRIAN BRUENGGER ----------------------------------------- Schaffhausen, Switzerland, JANUARY 30, 2006 Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) Form 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 4 Form 13F Information Table Entry Total: 18 Form 13F Information Table Value Total: $1,494,011 (thousands) List of Other Included Managers: Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.
No. Name - --- ---- 1 Biotech Focus N.V. 2 Biotech Invest N.V. 3 Biotech Target N.V. 4 Biotech Growth N.V.
BB BIOTECH AG FORM 13F INFORMATION TABLE
COLUMN 8 COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 ----------------------- - ----------------------- -------- --------- -------- -------------------- ---------- -------- VOTING AUTHORITY TITLE VALUE SHS OR SH/ PUT/ INVESTMENT OTHER ----------------------- NAME OF ISSUER OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ----------------------- -------- --------- -------- --------- --- ---- ---------- -------- --------- ------ ---- Affymetrix COM 00826T108 84,307 1,765,600 SH DEFINED 1 1,765,600 NONE NONE Amgen Inc. COM 031162100 98,575 1,250,000 SH DEFINED 1 1,250,000 NONE NONE Anadys Pharmaceuticals COM 03252Q408 17,600 2,000,000 SH DEFINED 3 2,000,000 NONE NONE Auxilium Pharmaceuticals, Inc. COM 05334D107 3,053 555,150 SH DEFINED 4 555,150 NONE NONE Biogen Idec Inc. COM 09062X103 226,400 5,000,000 SH DEFINED 1 5,000,000 NONE NONE Celgene Corporation COM 151020104 194,400 3,000,000 SH DEFINED 2 3,000,000 NONE NONE Elan Corporation, plc COM 284131208 33,432 2,400,000 SH DEFINED 2 2,400,000 NONE NONE Genentech COM 368710406 86,950 940,000 SH DEFINED 1 940,000 NONE NONE Genzyme Corporation COM 372917104 113,248 1,600,000 SH DEFINED 1 1,600,000 NONE NONE Gilead Sciences, Inc. COM 375558103 185,368 3,526,109 SH DEFINED 1 3,526,109 NONE NONE Incyte Corporation COM 45337C102 16,020 3,000,000 SH DEFINED 3 3,000,000 NONE NONE Keryx Biopharmaceuticals COM 492515101 6,010 410,499 SH DEFINED 3 410,499 NONE NONE OSI Pharmaceuticals COM 671040103 112,160 4,000,000 SH DEFINED 2 4,000,000 NONE NONE Rigel Pharmaceuticals COM 766559603 7,106 850,000 SH DEFINED 3 850,000 NONE NONE Sepracor Inc. COM 817315104 206,400 4,000,000 SH DEFINED 1 4,000,000 NONE NONE The Medicines Company COM 584688105 68,491 3,925,000 SH DEFINED 3 3,925,000 NONE NONE Theravance, Inc. COM 88338T104 4,054 180,000 SH DEFINED 4 180,000 NONE NONE Vertex Pharmaceuticals COM 92532F100 30,437 1,100,000 SH DEFINED 3 1,100,000 NONE NONE
-----END PRIVACY-ENHANCED MESSAGE-----